Amylyx Pharmaceuticals, Inc. (AMLX)

Amylyx Pharmaceuticals' stock has been impacted by several events in the past six months. The withdrawal of AMX0035 negatively impacted the stock, while a rally occurred in early 2025 due to the acquisition of avexitide. A KOL event on Avexitide led to a "Buy" rating from Citi. A public offering in September 2025 generated $191 million, bolstering its cash position. The Q3 2025 earnings report showed an EPS beat and a strong financial position. New safety data for AMX0114 was announced, and AMX0318 was selected as a development candidate. Insider selling occurred to cover tax obligations, and the stock experienced a decline reflecting biotech sector volatility.

There is no explicit indication of demand seasonality for Amylyx Pharmaceuticals, Inc.'s products or services. Demand is generally driven by disease prevalence and treatment needs rather than seasonal fluctuations.

Amylyx Pharmaceuticals, Inc., based in Cambridge, Massachusetts, is a biopharmaceutical company focused on discovering and developing treatments for neurodegenerative and endocrine diseases. Its product portfolio includes RELYVRIO (AMX0035), which was approved for ALS treatment but later withdrawn, Avexitide for post-bariatric hypoglycemia, AMX0114 for ALS, and AMX0318 for post-bariatric hypoglycemia and other rare diseases.

Amylyx Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts, United States. Its products were approved for use in the United States and Canada but have since been withdrawn from these markets. Clinical trials are conducted in the United States.

Amylyx Pharmaceuticals' brand reputation has been shaped by the withdrawal of AMX0035, but the company received praise for upholding its promise to withdraw the drug if it did not prove effective. Amylyx is working to rebuild its reputation through pipeline advancements and opportunities in orphan markets. Positive developments include Fast Track designation for AMX0114, nomination of AMX0318, and positive analyst ratings for avexitide. The company is committed to advancing new therapies for unmet needs.

Amylyx Pharmaceuticals, Inc. has a mixed ownership structure, with approximately 18.88% of the stock owned by institutional investors, 7.43% by insiders, and 14.87% by public companies and individual investors. Major institutional owners include Fmr Llc, Perceptive Advisors Llc, BlackRock, Inc., Adage Capital Partners Gp, L.l.c., TCG Crossover Management, LLC, Vanguard Group Inc, Saturn V Capital Management LLC, Commodore Capital Lp, First Light Asset Management, LLC, and Point72 Asset Management, L.P.. Co-CEOs Joshua Cohen and Justin Klee are among the founders, and Joseph Edelman owns the most shares among individual investors. Insider selling has occurred to cover tax obligations.